fda ruling on tirzepatide today F.D.A. Approves New Obesity Drug That Will Compete With Wegovy FDA says the tirzepatide weight-loss

Certainty of evidence At the class-level, certainty of evidence was highest for the GLP-1RA class compared with placebo, with high certainty observed for CV mortality, all-cause mortality, and non-fatal stroke, and moderate certainty for MACE and non-fatal MI, secondary to heterogeneity or imprecision for certain outcomes (Supplementary Table S25)

The role of GH and IGF-I in mediating anabolic effects of testosterone on androgen-responsive muscle

Dehydration Many people dont drink enough water while taking semaglutide

Generally, patients must have a BMI (body mass index) of at least 25 to benefit from this medication

While generally safe, GLP-1 medications are contraindicated for certain individuals